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Introduction Introduction
• Health related quality of life (HRQL) is a major concern in the 
clinical care of people living with HIV. 
• Measuring quality of life (QOL) is one way of assessing the 
patients experience with long term therapies  and other 
psychosocial dimensions  of living with the infection.
• Patient reported outcomes (PRO), measure HRQL – their use is 
mandatory during the drug approval process.
• PRO instruments currently used were devised for generic health 
assessment  and during the early  HAART period.
1. EMEA/CHMP/EWP/139391/2004. Reflection paper on the regulatory guidance for the use of
health-related quality of life (HRQL) measures in the evaluation of medicinal products. London,
EMEA, 2005.
2. 2. Draft Guidance for Industry – Patient-reported Outcomes Measures: Use in Medical Product
Development to support Labeling Claims. Docket 2006D-0044, FDA Federal Register, 2006.
Introduction Introduction
• A new Patient-Reported Outcomes questionnaire to measure QOL 
in people living with HIV/AIDS has been developed. 
• The instrument, PROQOL-HIV, has undergone psychometric 
validation in 791 individuals from 8 countries including 102 people 
from the WA HIV Cohort Study. 
Here we describe:
1. Factors influencing HRQL in the WA HIV Cohort Study
2. Some comparisons with other countries
3. The reliability and validity of the PROQOL-HIV 
questionnaire
METHODS
102 patients (792 globally) attending the Royal Perth 
Hospital Immunology Outpatient Clinic- completed 
three HRQL instruments: 
• (1) the 70-item PROQOL-HIV – to be tested
• (2) the EQ-5D
• (3) the MOS-HIV *
• (4) a symptom questionnaire
• Other information: Self reported missed doses in the preceding 
two weeks, demographic and biomedical data  ata 
The QOL score The QOL score† † from the PROQOL from the PROQOL- -HIV was expressed on a 0 HIV was expressed on a 0- -100  100 
point scale with higher values indicating better QOL. point scale with higher values indicating better QOL.
* *France, USA and Australia only,  France, USA and Australia only, †  † standardised standardised raw score raw score
METHODS: METHODS: (1) The PROQOL (1) The PROQOL- -HIV  Questionnaire HIV  Questionnaire
• • Ability to work Ability to work
• • Social life Social life
• • Stigma  Stigma 
• • Family Family
• • Sexuality  Sexuality 
• • Spirituality Spirituality
• • Medication  Medication 
• • Energy/fatigue Energy/fatigue
• • Psychological burden Psychological burden
• • Leisure  Leisure 
• • Ability to travel Ability to travel
• • Resources Resources
Qualitative input from semi directive interviews revealed 12 
dominant themes which informed the 70 item PROQOL-HIV 
questionnaire to be validated:
METHODS METHODS: (2) The  (2) The MOS-HIV SF 36
• general health 
perceptions
• physical functioning
• role functioning
• pain
• social functioning
• mental health 
• energy 
• health distress 
• cognitive functioning 
• quality of life
A physical health summary score: PHS A physical health summary score: PHS
A mental health summary score: MHS A mental health summary score: MHS2
METHODS: (3, 4) The EQ-5D & Symptom 
Questionnaire 
The EQ-5D is a standardised instrument for use as a 
generic measure of health outcome. It assess 5 
traits:
• Mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression together with a general 
health state scored on a visual analogue scale.
Symptoms/health conditions were measured using an 
modified version of the self completed HIV symptom 
index developed by Justice et al (2001)
1. Physical Health & Symptoms  (PHS)
2. Treatment Impact (TI) 
3. Emotional Distress (ED)
4. Health Concerns (HC)
5. Body Image (BC)
6. Intimate relationships (SR)
7. Social Relationships(IR)
8. Stigma (St)
PROQOL sub-scales 
RESULTS - Psychometric validation 
RESULTS: Patient characteristics: Australia
N=102
• Mostly caucasian(80%) men (85%)
• Agedbetween  37 – 53 yrs (mean 45)
• The earliest diagnosis was in 1981 with half of the patients 
diagnosed before 2000 (n=47) and half since (n=55)
• Transmissioncommonly msm (53%)
• Hetero = 27%, IVDU = 20%
• Living alone (39%) vs with a partner (33%) vs with others (28%) 
and employed (80% vs 18%)
• Most common co-morbidity:  depression (24%) followed by HCV 
(17%), psychiatric disorder (5%), CVD (3%) and HBV (2%)
RESULTS: Patient characteristics: Australia
antiretroviral therapy (ART),  n = 87
• 87 pts  on ART, 76% were 100% adherent
• 52% on protease inhibitors (PI)
• 70% on a once daily regimen
• 85% had an undetectable viral load
• Mean CD4T cell count ranged from 6 – 62% average 
= 26%
RESULTS:  RESULTS: Patients on protease inhibitors  Patients on protease inhibitors 
n = 42 (52%) n = 42 (52%)
• More likely to be on BD regimen (p= 0.01)
• Take more tablets (p<0.001)
• Report more symptoms (p=0.007)
RESULTS: PROQOL –HIV Score
All patients (n = 102) All patients (n = 102)
50.2, 64.4, 77.6 50.2, 64.4, 77.6
Naïve patients (n= 13) Naïve patients (n= 13)
48.1, 64.1, 77.6 48.1, 64.1, 77.6
Treated patients (n=87) Treated patients (n=87)
50.9, 65.4, 79.8 50.9, 65.4, 79.8
Lowest , median and highest score3
RESULTS: All Countries RESULTS: All Countries
Variable  West Australia
N = 102
All countries
N = 692
P - value
Gender m/f 85/15%      (87/15) 60/40%     (419/273) <0.001
Age (yrs) 45 41   <0.001
Body Mass Index 25 23 <0.001
Diagnosis (<2008) 3      7   16 2     5    9 <0.001
Transmission
Msm
Hetero
IVDU
53%   (54)
27%   (28)
20%   (20)
26%   (175)
55%   (374)
10%   (68)
<0.001
<0.001
NS
Living alone  39%  (40)  19% (131) <0.001
Secondary education 98%   (100) 19%   (126) <0.001
Demographics
RESULTS: All Countries RESULTS: All Countries
Variable  West Australia
N = 102
All countries
N = 692
P - value
Depression 24%   (24) 10 %   (67) 0.037
Psychiatric disorder 5%     (5) 6%      (41) NS
Hepatitis C  17% (17) 12% (72) NS
Hepatitis B 2% (2) 6%  (36) NS
Cardiovascular 
disease
3%    (3) 11%    (69) NS
Alcohol (>2/day) 15%    (15) 8%    (47) 0.027
Tobacco (>2/day) 40%   (41) 28%   (163) 0.008
Co-morbidities and Substances
RESULTS: All Countries RESULTS: All Countries
Variable  West Australia
N = 102
All countries
N = 692
P - value
Treatment/naive 85% (87) 86% (596) NS
Dosing schedule
OD, BD, >BD
70.5% (62) = OD
29.5 (26) = (BD)
0 = >BD
18%= OD
82%= (≥BD)
ART pill burden 3    5  <0.001
100% Adherence 
(last 2 weeks)
79% (84) 70% (512) <0.04
CD4 T Cell copies/ml 579 405 <0.001
Viral load 
(undetectable)
75%   (77) 85%   377 NS
No of symptoms 7 9 0.018
Treatments and Outcomes
RESULTS: Rank order of factors influencing  Rank order of factors influencing 
Quality of Life Quality of Life
Variable All Countries West Australia
Symptom burden (≥5) 1 2
Depression 2 1
Dosing schedule (≥BD) 3 6
Pill burden (>2tablets) 4 8
Psychiatric disorder 5 4
CD4 T-cell count (<200cps/ml) 6 7
Lack of Professional activity 7 3
Gender (female) 8 5
Living alone 9 7
Cardiovascular disease 10 9
PROQOL std score 47.4   60.8 61.3 50.2   64.4 7.6
RESULTS: Differences in sub-scales according to country
Australia, US & France
Brazil & Thailand
China & Cambodia
Senegal 
Social relationships
Physical health & 
symptoms
General 
health
Treatment 
impact
Body image
Health concerns
Emotional 
distress
Stigma
Intimate 
relationships
RESULTS: Differences in sub-scales according to country
Australia, US & France
Brazil & Thailand
China & Cambodia
Senegal 
Social relationships
Physical health & 
symptoms
General 
health
Treatment impact
Body image
Health concerns
Emotional 
distress
Stigma
Intimate 
relationships4
Relationship of depression to PROQOL subscales 
(Each sub-scale contributes equally)
Physical health & symptoms
General health
Stigma & intimate relationships
Emotional distress
& health concerns
Treatment impact
Depressed
Not depressed
20 40 60 80 100
N = 102 Western Australians 
RESULTS: Depression & Symptoms
• Participants who reported depression scored 
on average 13 points lower (95% CI, [-20.8;-
6.2]) 
• For each increase in the number of reported 
symptoms, there is a loss of about 2 points of 
HRQL (95% CI, [-2.3;1.1]).
RESULTS: RESULTS: Multivariate analysis  Multivariate analysis - -
Australians Australians
Number of symptoms   Number of symptoms   p < 0.001 p < 0.001
Depression  Depression  p < 0.001 p < 0.001
Living alone  Living alone  p = 0.005 p = 0.005
Younger age   Younger age   p = 0.003 p = 0.003
Heterosexual transmission Heterosexual transmission p = 0.008 p = 0.008
On a protease inhibitor On a protease inhibitor p = 0.046 p = 0.046
Linear Regression Analysis
Relative importance of scores
Depression Symptoms Age Transmission Treatment Pill burden Living
Lower scores were associated with more symptoms, depression, younger 
age, heterosexual transmission, not living with a partner, PI treatment and 
higher pill burden
Reliability and Validity
Q Is the PROQOL-HIV  a ‘valid’ PRO questionnaire? 
Does it measure what it is required to measure? 
Q Is the PROQOL-HIV  a ‘reliable’ PRO questionnaire? 
Are the observed scores reproducible when the 
questionnaire is readministered?
Physical Health 
Score
Mental Health 
Score
Joint distribution of PROQOL-HIV scores and the 
composite scores for MOS-HIV  PHS and MHS
R = 0.667                R = 0.8145
Joint distribution of 
PROQOL-HIV 
scores and EQ-5D 
*visual analogue 
score
The visual analogue scale = “your own health state today”: *
Best imaginable health state = 100%                              worst imaginable = 0%
VALIDITY
r = 0.632
RELIABILITY RELIABILITY
Scores reliability was assessed using 
￿ Cronbach’s alpha = 0.936 
￿ (95% CI = 0.929 – 0.943) 
￿ Intra- class correlation coefficient = 0.859
￿ (n= 34, 95% CI = 0.701-0.959) 
SUMMARY
In Western Australia in 2008
• The most significant health condition influencing 
quality of life was depression 
• 30% of depressed patients also had hepatitis C
• Depression and the number of reported symptoms 
were related
• People who acquired HIV heterosexually seem to 
have worse quality of life
• Patients on PIs reported more symptoms/health 
conditions
SUMMARY SUMMARY
￿ The PROQOL-HIV  is a ‘valid’ PRO questionnaire
It measures what it purports to measure
￿ The PROQOL-HIV  is a ‘reliable’ PRO questionnaire 
The scores observed are reproducible when the 
questionnaire is readministered
COMMENTS
There is an indication to examine: 
• The ‘social drivers’ of depression in the context of HIV and 
coinfections 
• The  role of stigma and shame and how stigma affects PLWHA
￿ There exists a need to 
• Consider how societal inequalities for example within gender 
and ethnicity are exacerbated by HIV and impact on QOL*
• Intervene to reduce substance use and prevent significant 
associated morbidity
*Kippax et al 2007
CONCLUSION
• The data demonstrate the validity and utility of the 
PROQOL-HIV to measure QOL in this population. 
• The implications of a high frequency of depression is 
concerning
• Rates of adherence are encouraging and are 
probably the outcome of active ongoing adherence 
support
• The information is a useful adjunct to national 
surveys and can be used to inform HIV services in 
WA. 6
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